Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M

Open source

DOI: 10.1016/s1470-2045(17)30231-0
Published: 2017 May
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-17-30231-0,
  title = {Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.},
  author = {Ascierto PA and Del Vecchio M and Robert C and Mackiewicz A and Chiarion-Sileni V and Arance A and Lebbé C and Bastholt L and Hamid O and Rutkowski P and McNeil C and Garbe C and Loquai C and Dreno B and Thomas L and Grob JJ and Liszkay G and Nyakas M and Gutzmer R and Pikiel J and Grange F and Hoeller C and Ferraresi V and Smylie M and Schadendorf D and Mortier L and Svane IM and Hennicken D and Qureshi A and Maio M},
  year = {2017},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(17)30231-0},
  url = {https://doi.org/10.1016/s1470-2045(17)30231-0}
}

RIS

TY  - JOUR
TI  - Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
AU  - Ascierto PA
AU  - Del Vecchio M
AU  - Robert C
AU  - Mackiewicz A
AU  - Chiarion-Sileni V
AU  - Arance A
AU  - Lebbé C
AU  - Bastholt L
AU  - Hamid O
AU  - Rutkowski P
AU  - McNeil C
AU  - Garbe C
AU  - Loquai C
AU  - Dreno B
AU  - Thomas L
AU  - Grob JJ
AU  - Liszkay G
AU  - Nyakas M
AU  - Gutzmer R
AU  - Pikiel J
AU  - Grange F
AU  - Hoeller C
AU  - Ferraresi V
AU  - Smylie M
AU  - Schadendorf D
AU  - Mortier L
AU  - Svane IM
AU  - Hennicken D
AU  - Qureshi A
AU  - Maio M
PY  - 2017
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(17)30231-0
UR  - https://doi.org/10.1016/s1470-2045(17)30231-0
ER  -

APA

PA, A., M, D. V., C, R., A, M., V, C., A, A., C, L., L, B., O, H., P, R., C, M., C, G., C, L., B, D., L, T., JJ, G., G, L., M, N., R, G., J, P., F, G., C, H., V, F., M, S., D, S., L, M., IM, S., D, H., A, Q., & M, M. (2017). Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(17)30231-0

Source records

pubmed · retrieved 2026-09-26T10:39:39.629Z